Bachelor of Arts in Clinical Psychology

SJW Group Appoints Marisa Joss as Corporate Secretary

Retrieved on: 
Wednesday, November 1, 2023

SJW Group (NYSE: SJW) today announced that its board of directors has appointed Marisa Joss as corporate secretary, effective October 25, 2023.

Key Points: 
  • SJW Group (NYSE: SJW) today announced that its board of directors has appointed Marisa Joss as corporate secretary, effective October 25, 2023.
  • Joss will also continue in her previous role as deputy general counsel subsidiaries, reporting to Willie Brown, vice president and general counsel of SJW Group.
  • View the full release here: https://www.businesswire.com/news/home/20231101083889/en/
    Marisa Joss appointed Corporate Secretary of SJW Group.
  • Prior to joining SJW Group, Marisa served as deputy general counsel and assistant corporate secretary for Eleusis, a biotech company based in New York and London, England.

Family Office Practice Expert Jim Coutré Joins Pathstone

Retrieved on: 
Monday, October 16, 2023

ENGLEWOOD, N.J., Oct. 16, 2023 /PRNewswire/ -- Pathstone - The Family Office, a partner-owned advisory firm offering comprehensive, highly customized investment advice and family office services, is pleased to announce the appointment of Jim Coutré as a new Managing Director and Head of the Wealth Planning Group to redefine the wealth planning offering and further develop Pathstone's increasing prominence in offering solutions for the complex technical and emotional challenges faced by ultra-high-net-worth families and offices. Mr. Coutré will be based in Pathstone's Boston office.

Key Points: 
  • Mr. Coutré comes as a trusted thought partner to wealth creators, multigenerational families, and their family office executives.
  • Mr. Coutré was previously the Vice President of Insights & Connections for Fidelity Family Office Services, a segment of Fidelity Institutional, where he delivered perspective and problem-solving across a wide range of family and family office matters to some of the world's most affluent families.
  • Recognized by his peers as a catalyst for new thinking on how to draw out the humanity in family office solutions, Mr. Coutré is one of the authors of Reshaping Reality: Unlocking the Potential of the Single Family Office.
  • He also holds the Advanced Certificate in Family Wealth Advising and the Advanced Certificate in Family Business Advising from the Family Firm Institute.

EmVenio Research expands clinical research team to streamline efficiency and compliance processes

Retrieved on: 
Monday, August 28, 2023

DURHAM, N.C., Aug. 28, 2023 /PRNewswire/ -- EmVenio Research recently appointed Christine Scheuring and Vickie Leathers to manage clinical research teams and processes. Scheuring serves as director of quality and compliance and Leathers is the manager of clinical research education and training. Their hiring aligns with EmVenio's goal to ensure that the clinical trial team conducts and will maintain adherence to the latest Federal Drug Administration regulations and in accordance with Good Clinical Practice and International Conference of Harmonization guidelines.

Key Points: 
  • DURHAM, N.C., Aug. 28, 2023 /PRNewswire/ -- EmVenio Research recently appointed Christine Scheuring and Vickie Leathers to manage clinical research teams and processes.
  • Scheuring serves as director of quality and compliance and Leathers is the manager of clinical research education and training.
  • EmVenio Research appointed Christine Scheuring and Vickie Leathers to manage its clinical research teams and processes.
  • "Adding Christine and Vickie reinforces our research team's effort to remain on the forefront of developments in the clinical research realm."

Molecular Templates Announces Executive Leadership Changes

Retrieved on: 
Wednesday, August 2, 2023

AUSTIN, Texas, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced executive management changes to implement its next phase of development.

Key Points: 
  • AUSTIN, Texas, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced executive management changes to implement its next phase of development.
  • These appointments were made to better enable Molecular Templates to execute on its clinical and corporate objectives.
  • Dr. Grace Kim joined Molecular Templates in 2022 with 20 years of experience driving investor strategy, corporate strategy, and business development.
  • These management changes will help enable us to execute efficiently in the clinic and in our corporate goals,” said Eric Poma, PhD., Chief Executive and Chief Scientific Officer of Molecular Templates.

EmVenio Research adds principal investigators to research team

Retrieved on: 
Tuesday, August 1, 2023

DURHAM, N.C., Aug. 1, 2023 /PRNewswire/ -- Clinical research organization EmVenio Research recently announced the addition of Dr. Stephen Blank, M.D., and Dr. Suzanne Swan, M.D., to its team, serving as principal investigators. In their roles, they will oversee and conduct objective clinical research to ensure independent, high quality and reproducible results, as well as manage oversight of compliance, financial, personnel and other related aspects of research projects. Coming from varying medical backgrounds, Dr. Blank and Dr. Swan offer a diversity of expertise, expanding EmVenio's ability to conduct a wider range of clinical trials.

Key Points: 
  • DURHAM, N.C., Aug. 1, 2023 /PRNewswire/ -- Clinical research organization EmVenio Research recently announced the addition of Dr. Stephen Blank, M.D., and Dr. Suzanne Swan, M.D., to its team, serving as principal investigators.
  • Stephen Blank and Suzanne Swan to its team of principal investigators.
  • Blank and Swan bring to our team a magnitude of experience and knowledge in the research of new treatments and therapies," said Thad Wolfram, EmVenio president.
  • "With their diverse backgrounds in medicine, they offer a unique level of oversight to the studies EmVenio conducts and provide our organization the depth to conduct a wider range of clinical research studies for pharmaceutical and clinical research organizations."

Andrew T. Leitner, M.D., appointed chair of City of Hope Department of Supportive Care Medicine

Retrieved on: 
Monday, April 17, 2023

LOS ANGELES, April 17, 2023 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States and a national leader in providing cancer patients with best-in-class, integrated supportive care programs, announced today that Andrew T. Leitner, M.D., has been appointed chair of the Department of Supportive Care Medicine and Arthur M. Coppola Family Chair in Supportive Care Medicine.

Key Points: 
  • LOS ANGELES, April 17, 2023 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States and a national leader in providing cancer patients with best-in-class, integrated supportive care programs, announced today that Andrew T. Leitner , M.D., has been appointed chair of the Department of Supportive Care Medicine and Arthur M. Coppola Family Chair in Supportive Care Medicine.
  • Andrew T. Leitner, M.D., has been appointed chair of City of Hope Department of Supportive Care Medicine.
  • The Department of Supportive Care Medicine at City of Hope was the first in the United States to fully integrate across supportive care specialties and into the patient's clinical care and is one of the largest programs of its kind today.
  • "Our focus in supportive care medicine for cancer patients is to expand access to our evidence-based supportive care offerings and advocate for a national standard of care.

Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics

Retrieved on: 
Friday, March 24, 2023

SOUTH PLAINFIELD, N.J., March 24, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT). Stuart Peltz, Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced today that he is stepping down after 25 years. Dr. Peltz has led PTC Therapeutics as its CEO since its founding in 1998 and pioneered the field of RNA-directed drug development. Under his leadership, PTC has grown from a research organization with expertise in the control of RNA processes to a publicly traded, integrated, global biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for the treatment of neurological and neuromuscular disorders, metabolic disorders, and cancer.

Key Points: 
  • Stuart Peltz, Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced today that he is stepping down after 25 years.
  • Dr. Peltz has led PTC Therapeutics as its CEO since its founding in 1998 and pioneered the field of RNA-directed drug development.
  • What Stuart and the team have achieved in 25 years is extraordinary," said Michael Schmertzler, Chairman of the Board of Directors.
  • Matthew Klein, M.D., M.S., F.A.C.S., current Chief Operating Officer, has been named the company's CEO and will join the Board of Directors.

AutoCruitment Adds to Executive Team; Opens New Raleigh, North Carolina, Office

Retrieved on: 
Tuesday, March 14, 2023

Additionally, the Company announced the new North Carolina office location where both executives will be based.

Key Points: 
  • Additionally, the Company announced the new North Carolina office location where both executives will be based.
  • Twiddy joins AutoCruitment from ChannelAdvisor where she served as General Counsel of the global e-commerce SaaS company, which went private in November 2022.
  • She received a Bachelor of Arts and a Juris Doctor with honors from the University of North Carolina at Chapel Hill.
  • Additionally, the Company announced the opening of an office in Raleigh that will support the executive leadership team as well as future expansion and growth.

Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary

Retrieved on: 
Monday, November 7, 2022

BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately.

Key Points: 
  • BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately.
  • Mr. Ian Mortimer, Xenons President and Chief Executive Officer, stated, We are very pleased to welcome Andrea to Xenons senior leadership team in the newly created role of Chief Legal Officer.
  • From 2019 to 2020, Ms. DiFabio served as Chief Legal Officer and Corporate Secretary at Codiak Biosciences, Inc.
  • Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.

Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer

Retrieved on: 
Monday, October 17, 2022

Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, announced the appointment of Lyn Baranowski as chief executive officer.

Key Points: 
  • Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, announced the appointment of Lyn Baranowski as chief executive officer.
  • Ms. Baranowski brings more than two decades of experience leading a vast array of functions in biotech, big pharma and venture capital firms.
  • Under his leadership, Avalyn built a strong scientific foundation, from which it will be well positioned to advance its business and clinical development objectives, stated Niall O'Donnell, chairman of the Avalyn board of directors.
  • Prior to joining Avalyn, Ms. Baranowski served as chief operating officer at Altavant Sciences, a biopharmaceutical company developing a portfolio of therapies for rare respiratory diseases.